middle.news
Nexsen posts $6.55m loss in FY26 as clinical trials and Asia-Pacific expansion gain momentum
7:54am on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Nexsen posts $6.55m loss in FY26 as clinical trials and Asia-Pacific expansion gain momentum
7:54am on Monday 31st of August, 2026 AEST
Key Points
30% increase in net loss to $6.55 million
IPO raised $8 million at 20 cents per share
Clinical trials commenced for StrepSure GBS rapid sensor
Secured HK$6 million Ignite grant and Hong Kong hospital partnership
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexsen (ASX:NXN)
OPEN ARTICLE